| Ticker Details |
Veracyte, Inc.
Veracyte Inc is a molecular diagnostics company that uses genomic technology to resolve diagnostic ambiguity. The Company's first commercial solution, the Afirma Thyroid FNA Analysis, centers on the proprietary Afirma Gene Expression Classifier.
|
| IPO Date: |
October 30, 2013 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$3.4B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.65 | 2.70%
|
| Avg Daily Range (30 D): |
$1.35 | 2.59%
|
| Avg Daily Range (90 D): |
$1.28 | 2.71%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.42M |
| Avg Daily Volume (30 D): |
1M |
| Avg Daily Volume (90 D): |
.91M |
| Trade Size |
| Avg Trade Size (Sh.): |
61 |
| Avg Trade Size (Sh.) (30 D): |
54 |
| Avg Trade Size (Sh.) (90 D): |
50 |
| Institutional Trades |
| Total Institutional Trades: |
3,971 |
| Avg Institutional Trade: |
$2.96M |
| Avg Institutional Trade (30 D): |
$4.31M |
| Avg Institutional Trade (90 D): |
$4.83M |
| Avg Institutional Trade Volume: |
.09M |
| Avg Institutional Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$4.53M |
| Avg Closing Trade (30 D): |
$11.62M |
| Avg Closing Trade (90 D): |
$11.92M |
| Avg Closing Volume: |
142.5K |
|
|
| Financials |
| |
TTM |
Q2 2026 |
Q1 2026 |
|
Basic EPS
|
$1.44
|
$.32
|
$.36
|
|
Diluted EPS
|
$1.4
|
$.31
|
$.35
|
|
Revenue
|
$561.9M
|
$150.32M
|
$139.07M
|
|
Gross Profit
|
$402.96M
|
$108.55M
|
$101.16M
|
|
Net Income / Loss
|
$114.48M
|
$25.49M
|
$28.71M
|
|
Operating Income / Loss
|
$105.77M
|
$22.98M
|
$22.65M
|
|
Cost of Revenue
|
$158.94M
|
$41.77M
|
$37.91M
|
|
Net Cash Flow
|
$80.03M
|
$36.39M
|
$-99.43M
|
|
PE Ratio
|
|
|
|
|
|
|
